Summer Intern - Patient Advocacy

Karyopharm Therapeutics Inc.

Jan 23, 2024

Applications are closed

Internship
Full-time
Starts on May 26
Summer Internship
Science
United States
Remote

Similar opportunities

Explore more

Junior Research Technician (Student)

Internship•Givaudan

Placement Program

Industrial Chemist Intern

Internship•Coty

Off-cycle Internship

R&D Intern

Internship•BD

Summer Internship

Intern / Temporary Operations Support - 1st shift (7AM-3:30PM)

Internship•Hill's Pet Nutrition

Off-cycle Internship

Summer 2025 Internship Program - Analytical Laboratory Intern - Princeton, NJ

Internship•dsm-firmenich

Summer Internship

Requirements

Currently pursuing Bachelors/Master’s degree and interested in advocating on behalf of patients.
Ability to collaborate and interact with individuals at all levels.
Performs well under pressure and delivers results.
Awareness of core pharmaceutical business metrics; good knowledge of current affairs.
Strategic, critical and creative thinking skills; Sound judgment and impeccable discretion in handling sensitive and confidential information.
You have a strong interest in life sciences and are passionate about giving patients with cancer a chance to enjoy more of life’s precious moments.
You feel a strong connection with our ICARE values (Innovation, Courage, Alignment & Accountability, Resilience, and Energy)
You demonstrate enthusiasm for learning and a commitment to career development

Responsibilities

Partner with internal stakeholders and patient advocacy groups to support the development and delivery of initiatives that increase disease awareness and clinical trials resulting in increased patient enrollment.
Engage with a cross functional internal team to advance decisions regarding grants and sponsorships.
Collaborate internally with functional leaders and global partners to amplify the patient voice within Karyopharm.
In partnership with appropriate internal stakeholders, gather and champion the patient perspective through involvement with advisory boards and working groups focused on helping Karyopharm gain insights from the communities we serve

Karyopharm Therapeutics Inc.

Targeting Disease at the Nuclear Pore

Manufacturing & Electronics

Industry

201-500

Employees

2008

Founded Year

Mission & Purpose

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.